african/homa

Kiungo kimehifadhiwa kwenye clipboard

Chagua aina ya aina

14 matokeo

Attenuated African swine fever virus vaccine

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

FIELD OF THE INVENTION The present invention relates to attenuated African Swine Fever Viruses. The engineered viruses protect pigs against subsequent challenge with virulent virus. The present invention also relates to the use of such attenuated viruses to treat and/or prevent African Swine Fever.

Attenuated African swine fever virus vaccine based in the deletion of MGF genes

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND OF THE INVENTION Field of the Invention This invention relates to the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated candidate strain vaccine for the highly virulent Georgia 2007 isolate ASFV-G. The vaccine comprises the ASFV-G .DELTA.MGF, a recombinant

African swine fever virus georgia strain adapted to efficiently grow in the vero cell line

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the field of viruses for vaccine development useful in the prophylaxis of African Swine Fever (ASF). More specifically, the invention provides a novel ASF virus for the development of recombinant ASF

Antiviral peptides from african swine fever virus which prevent the binding of the virus to DLC8

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

FIELD OF THE INVENTION This invention relates to the technical field of development of new antiviral compounds and their use in the prevention or treatment of virus infections in animals or human beings. BACKGROUND OF THE INVENTION Viruses are intracellular parasites which require the integrity of

Rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Attenuated african swine fever virus strain induces protection against challenge with homologous virulent parental virus georgia 2007 isolate

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated candidate strain vaccine for the highly virulent Georgia 2007 isolate ASFV-G. The vaccine comprises the ASFV-G .DELTA.9GL, a recombinant

Tick galectin

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

TECHNICAL FIELD This invention relates to a tick galectin. BACKGROUND ART Ticks are the cause, directly or indirectly, of extensive damage to animals or humans. Examples of the direct damage are pruritus or bleeding caused by biting or blood-sucking, or tick paralysis or allergic diseases caused by

Tick galectin

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Mite galectin

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Genetically edited pigs comprising a modification in the RELA gene

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

The present invention relates to a genetically edited non-human animal. In particular the invention relates to a genetically edited mammal, and particularly to a genetically edited pig. The animal is less affected by pathogen infection; in particular the animal is less likely to develop disease

Ubiquitin conjugating enzymes 7, 8 and 9

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are Ubiquitin

Ubiquitin conjugating enzymes 8 and 9

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Ubiquitin conjugating enzymes 7,8 and 9

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

This application is entitled to the benefits of 35 U.S.C. .sctn.120 for priority based on PCT/US95/01250, filed 31 Jan. 1995. This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the

Ubiquitin conjugating enzymes 8 and 9

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

This application is entitled to the benefits of 35 USC .sctn.120 for priority based on PCT/US95/01250, filed 31 Jan. 1995. This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the

Jiunge na ukurasa
wetu wa facebook

Herbal & Natural Medicine

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi

Inafanya kazi katika lugha 55
Uponyaji wa mitishamba unaungwa mkono na sayansi
Kutambua mimea kwa picha
Ramani ya GPS inayoshirikiana
Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
Tafuta mimea ya dawa na athari zao
Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu

Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa